Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
Recruiting · NCT07710885 · Registry updated 2026-07-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer | Biliary Tract Neoplasms, Bone Diseases, Developmental, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Craniofacial Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Limb Deformities, Congenital, Musculoskeletal Abnormalities, Neoplasms by Site, autosomal dominant Parkinson disease 4, biliary tract cancer, biliary tract disorder, bone disorder, craniosynostosis, dysostosis, musculoskeletal system disorder, neoplasm, syndactyly, synostosis | Recruiting | Phase 3 | 2026-07-17 | NCT07710885 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Taiho Oncology, Inc. | 24 |
| Taiho Pharmaceutical Co., Ltd. | 8 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Kanagawa Cancer Center | Kanagawa | Japan | 5 |
| National Hospital Organization Kyushu Cancer Center | Fukuoka | Japan | 6 |
| The Cancer Institute Hospital | Tokyo | Japan | 1 |
| Toyama University Hopspital | Toyama | Japan | 1 |
| Wakayama Medical University Hospital | Wakayama | Japan | 4 |